EMCDDA Technical conference on the key indicators: 20 years of monitoring, 21-22 September 2015, Lisbon
EMCDDA Conference on 20 years of monitoring and communicating evidence on drugs
21-22 September 2015, Lisbon
Understanding the nature, dynamics and scale of drug use in Europe
Understanding the dynamics, nature and scale of drug use in Europe, including lessons learnt and challenges for the future, has been the focus of this EMCDDA conference held in Lisbon from 21–22 September 2015. The event commemorated the EU agency’s 20 years of monitoring and communicating evidence on drugs.
Building on national and early European activities, the EMCDDA has worked for the last two decades to improve the monitoring of Europe’s drug problems. At the heart of its activity have been efforts to enhance the comparability of drug information across Europe and to devise the standards, methods and tools required to achieve this. Among the agency’s core achievements are its five key epidemiological indicators (KI), supported by European expert groups, which allow countries to describe in a ‘common language’ the extent and nature of drug use and its consequences.
The conference aimed to reflect on past successes but also to be forward-looking. Key issues to help the EMCDDA better achieve its aims include: increased data quality and comparability; improved timeliness; better identification of emerging trends; faster and more sensitive monitoring approaches; and the integration of traditional and new monitoring methods (e.g. wastewater analysis, internet surveys). The ultimate aim of this milestone event will be to contribute to reducing drug-related harms through better informed and faster evaluated policies.
Presentations
- Session 1
- Session 2
- Session 3
- Session 4 - Workshop 1
- Understanding drug trends and developments (surveys and related data GPS group) - Julián Vicente and João Matias
- France: Findings from last French National Survey (2014) and trends - Stanislas Spilka
- Finland: Results from the Finnish 2014 Drug Survey - Karolina Karjalainen
- CTC-EU: Results and perspectives of the CTC-EU project on drug prevention - Harrie Jonkman
- Session 4 - Workshop 2
- Session 4 - Workshop 3
- Session 4 - Workshop 4
- France: MDMA-related deaths – trends and concerns - Michel Mallaret and Joëlle Micallef
- Overview on the French story of Ecstasy - Magali Martinez and Anne-Claire Brisacier
- Belgium: ICD coding issues in DRD in Belgium - Karin De Ridder
- Italy: Impact of different selection of ICD codes in the Italian GMR - Roberta Crialesi
- EMCDDA and Malta: Codifications practices of DRD following the WHO revision guidelines, a European review - Isabelle Giraudon and Kathleen England
- Session 5
- Hungary: Injection of NPS, multi-indicator analysis - Anna Tarján
- Romania: Drug issues in Roma communities in Romania - Ruxanda Illiescu
- France: Use and misuse of medicines among French drug users - Agnes Cadet-Tairou
- Latvia: Multipurpose studies. Follow-up study of high-risk drug users in Latvia - Marcis Trapencieris
- France: Qualitative studies to identify and analyse drug trends, TRENDS System - Agnès Cadet-Tairou
- Extending our vision: Reflections on the presentations - Nicola Singleton
- Session 6 - Workshop 5
- EMCDDA: Introduction - Alessandro Pirona
- Austria: Inclusion of settings in treatment monitoring - Alexander Grabenhofer-Eggerth
- Greece: Inclusions of service provision and performance - Anastasios Fotiou
- Czech Republic: Availability and quality assurance of specialised addiction treatment facilities - Barbara Janikova
- Session 6 - Workshop 6
- Session 6 - Workshop 7
- Austria: Strategic considerations to decrease HCV prevalence in Austria - Martin Busch
- EMCDDA: Prices of the new generation of HCV medicines - Claudia Costa Storti
- Poland: Recent HCV data and their implications for extension of harm reduction measures including injection rooms - Janusz Sieroslawski
- United Kingdom: Intervention effectiveness to prevent HCV among people who inject drugs - Peter Vickerman
- Session 6 - Workshop 8
- EMCDDA: Introduction on polysubstance use and context. Polydrug use among high-risk drug users in Europe - Linda Montanari
- Finland: Results on the new polydrug use questions in the Finnish TDI - Martta Forsell
- Netherlands: Trends and patterns in polyaddiction in the Netherlands, data from the National Alcohol and Drug Information System - Jeroen Wisselink
- Session 7 - Workshop 9
- Session 7 - Workshop 10
- Session 7 - Workshop 11
- Session 8
Posters